Physician profile

Stephen C Koehler

Hematology & Oncology · South Pasadena, CA

NPI 1487761433

$1,187.13

in general payments reported to CMS, 2019-2025

18 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Education$21.70

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
E.R. Squibb & Sons, L.L.C. $337.33 2019
Janssen Biotech, INC. $236.90 2019-2020
Merck Sharp & Dohme LLC $128.54 2019
Amgen INC. $96.28 2019-2022
Pfizer INC. $68.18 2019-2022
Astellas Pharma US INC $57.01 2019-2020
Genentech USA, INC. $46.95 2019-2020
Eisai INC. $32.66 2019
Astrazeneca Pharmaceuticals LP $32.25 2019
Seagen INC. $24.41 2020
Janssen Pharmaceuticals, INC $21.70 2024
Lilly USA, LLC $21.08 2019
Array Biopharma INC $18.43 2019
Bayer Healthcare Pharmaceuticals INC. $17.11 2019
Incyte Corporation $16.61 2021
Show all 18 companies
CompanyGeneral paymentsYearsTop products
Rigel Pharmaceuticals, INC. $11.82 2019
Tactile Systems Technology INC $11.11 2019
Fortovia Therapeutics, INC. $8.76 2020

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Stephen C Koehler

$1,187.13

in general payments reported 2019-2025

Years
2019-2024
Top company
E.R. Squibb & Sons, L.L.C.

https://glasscript.com/doctor/294535/stephen-c-koehler

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.